Vianna R
Unit of Intestinal and Multivisceral Transplantation, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202-5250, USA.
Minerva Pediatr. 2009 Jun;61(3):293-303.
Recent advances in intestinal transplantation have made this treatment option an acceptable clinical reality for many patients with intestinal failure. Growth in this field is closely linked to an improved understanding of the intrinsic immune system of the intestine, and the development of immunosuppression agents that interact with this system. The recent advent of antibody-based immunosuppression induction agents has decreased perioperative rejection episodes and lowered the amount of maintenance immunosuppression required by intestinal transplant patients. As progress is made in lowering the risks of graft rejection, long-term outcomes will continue to improve and a greater number of patients with intestinal failure will benefit from this therapy.
肠道移植领域的最新进展已使这种治疗选择成为许多肠衰竭患者可接受的临床现实。该领域的发展与对肠道固有免疫系统的深入理解以及与该系统相互作用的免疫抑制药物的开发密切相关。基于抗体的免疫抑制诱导剂的最新出现减少了围手术期的排斥反应，并降低了肠道移植患者所需的维持性免疫抑制剂量。随着在降低移植物排斥风险方面取得进展，长期预后将持续改善，更多的肠衰竭患者将从这种治疗中受益。
